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A cytotoxic analysis of antiseptic 
medication on skin substitutes and 
autograft
Antibacterial agents are frequently used on human skin 
substitutes (HSSs) for treating difficult-to-heal ulcers, as 
infection or bacterial colonization can cause the graft to 
fail. Twelve different antiseptic agents were tested on two 
different HSS models (autologous reconstructed epidermis 
on fibroblast-populated dermis and allogeneic reconstruct-
ed epidermis on a fibroblast-populated collagen gel). The 
degree of cytotoxicity was analysed by detrimental changes 
in histology, metabolic activity and RNA staining of tissue 
sections. Acticoat®, Aquacel Ag®, Dermacyn®, Fucidin®, 
0.5% silver nitrate solution and chlorhexidine digluconate 
were not cytotoxic for either HSS or autograft, and can 
therefore be used as required. Flamazine® and zinc oxide 
cream resulted in moderate cytotoxicity. However, appli-
cation of Betadine®, cerium-silver sulfadiazine cream, sil-
ver sulfadiazine cream with 1% acetic acid and Furacine® 
resulted in a substantial decrease in cell viability and a det-
rimental effect on tissue histology when applied to autograft 
and especially to HSS. Br J Dermatol 2007; 157:33–40.
Sentinel lymph node biopsy in 
melanoma: a micromorphometric 
study relating to prognosis and 
completion lymph node dissection
Sentinel lymph node (SLN) biopsy still remains controver-
sial. However, this large series of patients studied (n = 455) 
has confirmed the prognostic value of SLN biopsy. It also 
confirmed the relationship between the tumour burden in 
the SLN (evaluated by the maximum diameter of the largest 
metastasis) and the clinical outcome. Br J Dermatol 2007; 
157:58–67.
Prevalence of metabolic syndrome 
in patients with psoriasis: a hospital-
based case–control study
The aim of this study was to investigate the prevalence 
of metabolic syndrome in patients with psoriasis. Adult 
patients with chronic plaque psoriasis (n = 338) and 
patients with skin diseases other than psoriasis (n = 334) 
were studied. Metabolic syndrome was significantly more 
common in psoriatic patients than in controls (30.1% vs. 
20.6%; odds ratio 1.65; 95% confidence interval 1.16–
2.35; P = 0.005) after the age of 40 years. Psoriatic patients 
had also a higher prevalence of hypertriglyceridaemia 
and abdominal obesity, whereas hyperglycaemia, arterial 
hypertension and plasma levels of high-density lipoprotein 
cholesterol were similar. Although patients with psoriasis 
were more frequently smokers, the association of psoriasis 
with metabolic syndrome was independent from smoking. 
There was no correlation between severity of psoriasis and 
prevalence of metabolic syndrome. Psoriatic patients with 
metabolic syndrome were older and had a longer disease 
duration compared with psoriatic patients without meta-
bolic syndrome. Br J Dermatol 2007; 157:68–73.
Post-traumatic lipomas: fact or fiction?
Is there a link between blunt soft tissue trauma and the for-
mation of lipomas? Thirty-four cases of post-traumatic lipo-
mas in 31 patients were studied. The mean time elapsed 
between soft tissue trauma and lipoma formation was 
2.0 years (range 0.5–5). Twenty-five of the 31 patients 
reported an extensive and slowly resolving haematoma 
after the traumatic event. Eleven of 34 lipomas were found 
on the upper extremities, five on the lower extremities, 
13 on the trunk, and two on the face. All tumours were 
located subcutaneously. Fourteen patients presented with 
an elevated partial thromboplastin time. There are two 
potential explanations to correlate blunt soft tissue trauma 
and the formation of post-traumatic lipomas: (i) the forma-
tion of so-called post-traumatic ‘pseudolipomas’ by pro-
lapsing adipose tissue through fascia resulting from direct 
impact, and (ii) lipoma formation as a result of preadipocyte 
differentiation and proliferation mediated by cytokine 
release following soft tissue damage and haematoma for-
mation. Br J Dermatol 2007; 157:92–99.
Mycophenolate mofetil for severe 
childhood atopic dermatitis: 
experience in 14 patients
Mycophenolate mofetil (MMF) has been used in adults 
with severe atopic dermatitis with some success. Heller 
et al. retrospectively studied 14 children with recalcitrant 
atopic dermatitis. Four patients (29%) achieved complete 
clearance, four (29%) had > 90% improvement (almost 
complete), five (35%) had 60–90% improvement and one 
(7%) failed to respond. Initial responses occurred within 
8 weeks (mean 4 weeks), and maximal effects were attained 
after 8–12 weeks (mean 9 weeks) at MMF doses of 40–50 
mg kg–1 daily in younger children and 30–40 mg kg-1 daily 
in adolescents. The medication was well tolerated in all 
patients, with no infectious complications or development 
of leucopenia, anaemia, thrombocytopenia or elevated 
aminotransferases. MMF can be a safe and effective treat-
ment for severe, refractory atopic dermatitis in children. 
Br J Dermatol 2007; 157:1271–32.
